INS and portal hypertension: Furthermore, while all patients met criteria for clinically significant portal hypertension at baseline, by the end of the study, patients in the SGLT2i group experienced a significant reduction in both liver stiffness by TE (from 28.5 ± 0.8 to 24.5 ± 0.7 kPa) and ARFI-SWV (from 2.9 ± 0.1 to 2.5 ± 0.1 m/s), whereas no improvement was observed in the insulin group.